An observational study in Facial Rhytides, sponsored by Allergan. Completed at 1 site in Argentina. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-04-17.
Sponsored by Allergan · Observational
This is a retrospective chart review to evaluate treatment patterns of botulinum toxin Type A for the treatment of facial lines.
Allergan is the lead sponsor of 499 studies on the registry; none are open to participants now.
Of its 91 completed or terminated interventional studies of FDA-regulated products, 89 (98%) have results posted.
Counted across the registry records on this site, refreshed daily.
Subjects treated for glabellar lines (hyperfunctional facial lines) with botulinum toxin Type A
Exclusion Criteria:
Previous treatment with botulinum toxin Type A for treatment of facial lines
Drug: botulinum toxin Type A
Previous treatment with botulinum toxin Type A for treatment of facial lines
Also known as: BOTOX®, Xeomin®
Average Total Dose Per Treatment Period
Average total dose per treatment period was defined as total treatment dose plus total touch-up dose plus total follow-up dose.
Time frame: 24 Months
Inter-Injection Interval Duration of Each Treatment Period
Inter-injection interval duration of each treatment period. Duration is defined as the number of days of an injection cycle.
Time frame: 24 Months
Percent of Subjects Reporting Satisfaction With Treatment Effects
Percent of subjects reporting satisfaction with treatment effects per chart notes.
Time frame: 24 Months
| Milestone | Botulinum Toxin Type A |
|---|---|
| Started | 110 |
| Completed | 94 |
| Not completed | 16 |
Average total dose per treatment period was defined as total treatment dose plus total touch-up dose plus total follow-up dose.
| Units | Botulinum Toxin Type A |
|---|---|
| Treatment Period 1 (BOTOX®) N=34 | 49.2 ± 12.77 |
| Treatment Period 2 (Xeomin®) N=34 | 48.1 ± 15.18 |
| Treatment Period 3 (BOTOX®) N=16 | 45.8 ± 4.68 |
Inter-injection interval duration of each treatment period. Duration is defined as the number of days of an injection cycle.
| Days | Botulinum Toxin Type A |
|---|---|
| Treatment Period 1 (BOTOX®) N=110 | 180.3 ± 94.40 |
| Treatment Period 2 (Xeomin®) N=106 | 144.3 ± 113.55 |
| Treatment Period 3 (BOTOX®) N=76 | 176.9 ± 91.43 |
Percent of subjects reporting satisfaction with treatment effects per chart notes.
| Percentage of Subjects | Botulinum Toxin Type A |
|---|---|
| Treatment Period 1 (BOTOX®) N=80 | 99.0 ± 6.68 |
| Treatment Period 2 (Xeomin®) N=74 | 33.7 ± 39.29 |
| Treatment Period 3 (BOTOX®) N=67 | 90.3 ± 17.56 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Botulinum Toxin Type A | — | — | — |
| Age, Customized(Participants) | Botulinum Toxin Type A |
|---|---|
| ≥30 and <40 years | 5 |
| ≥40 and <50 years | 31 |
| ≥50 and <60 years | 33 |
| ≥60 years | 35 |
| Missing | 6 |
| Sex: Female, Male(Participants) | Botulinum Toxin Type A |
|---|---|
| Female | 110 |
| Male | 0 |
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Allergan